Y medicine officially landed!

Preface: As the country approved the use of Iraq horses adalimumab (the I pilimumab , trade name Yervoy , vulgar called Y drugs ) of the first medical institutions, Kerry will be the International Cancer Center by 2 021 January 0 since January 12, the first to meet the domestic approved adaptation syndrome patient with drug Y is based on double immunotherapy-related services, including drug program evaluation, post-treatment and the use of adverse reaction monitoring and care , move faster to help patients with malignant pleural mesothelioma secure more Treatment opportunities will benefit more domestic patients from the wave of the immunization era
.



On June 10, 2021, the first domestic CTLA-4 inhibitor ipilimumab was approved by the National Medical Products Administration (NMPA) in combination with Nivolumab (Nivolumab, trade name Opdivo, commonly known as O drug) The first-line treatment of patients with untreated, unresectable, non-epithelioid malignant pleural mesothelioma[1] means that the " Y drug + O drug" dual immune combination therapy for the treatment of pleural mesothelioma is officially approved in China
.

 Preface: As the country approved the use of Iraq horses adalimumab (the I pilimumab , trade name Yervoy , vulgar called Y drugs ) of the first medical institutions, Kerry will be the International Cancer Center from 2021 January 0 since January 12, the first to adapt to meet the domestic approval certificate provided Y patients with drug -based treatment of immune-related dual services, including drug program after the assessment, medication use and adverse reaction monitoring and care , ancestors One step is to help patients with malignant pleural mesothelioma gain more treatment opportunities, so that the wave of the immune era will benefit more domestic patients
.



On June 10, 2021, the first domestic CTLA-4 inhibitor ipilimumab was approved by the National Medical Products Administration (NMPA) in combination with Nivolumab (Nivolumab, trade name Opdivo, commonly known as O drug) The first-line treatment of patients with untreated, unresectable, non-epithelioid malignant pleural mesothelioma[1] means that the " Y drug + O drug" dual immune combination therapy for the treatment of pleural mesothelioma is officially approved in China
.

 Preface: As the country approved the use of Iraq horses adalimumab (I Introduction: As the country approved the use of Iraq horses adalimumab (I pilimumab pilimumab , trade name , trade name Yervoy Yervoy , vulgar , vulgar called Y drugs known as drug Y ) of Leading medical institution, Jiahui International Cancer Center from 2 ) Leading medical institution, Jiahui International Cancer Center from 2021 021 Year 1 Year 1 0 0 since May 12, took the lead on the 12th month, the first country to adapt to meet the approval is granted to adapt to meet the domestic certificate of license to provide patients with drug Y provide patients with drug Y based on double immunotherapy related dual immune-based therapy-related services, including drug program after the assessment, treatment and use of services, including program evaluation after treatment, medication use and adverse reactions adverse reactions monitoring and care monitoring and care , one step ahead of vicious help Patients with pleural mesothelioma are striving for more treatment opportunities, and the first step is to help patients with malignant pleural mesothelioma to gain more treatment opportunities, so that the wave of the immune era will benefit more domestic patients
.
Let the wave of the immunization era benefit more domestic patients
.



This means that the " Y drug + O drug" dual immune combination therapy for the treatment of pleural mesothelioma has been officially approved in China
.


Source: China National Medical Products Administration official website "June 10, 2021 Drug Approval Documents Pending Information Release"
Source: China National Medical Products Administration Official Website "June 10, 2021 Drug Approval Documents Pending Information Release" released "
Figure source: China State Drug Administration official website," June 10, 2021 to receive approval documents, the information to be released, " the immune Gemini, open a new pattern of malignant pleural mesothelioma treatment of malignant pleural mesothelioma (malignant pleural mesothelioma , MPM) is a rare tumor derived from pleural mesothelial cells.
According to histological type, it is mainly divided into epithelioid and non-epithelial .
Malignant pleural mesothelioma is characterized by its insidious onset and highly aggressive nature.
Most patients are already in advanced stages when they are first diagnosed.
Treatment is difficult and the prognosis is poor .
However, MPM treatment options are very limited.
The median overall survival of MPM patients is about 1 year, and the 5-year survival rate is less than 10% [2].
Patients urgently need new treatment options to improve treatment effects and prolong survival.
However, before Various clinical treatment effects are not satisfactory .
"The combination therapy of Y drug + O drug" was confirmed in a multi-center, open-label, randomized phase III clinical trial (CheckMate 743) study: Compared with standard chemotherapy (platinum combined with pemetrexed), this Combined treatment of previously untreated patients with unresectable MPM, the median overall survival (mOS) was extended by 4 months (18.
1 months vs.
14.
1 months), and the median objective response time (mDOR) was increased by 5.
9 months ( 11.
6 months vs.
6.
7 months), the risk of death was reduced by 27% (HR 0.
73; 95% CI: 0.
61-0.
87); the overall survival (OS) of non-epithelial MPM and epithelial MPM in the experimental group was similar, but the standard The mOS of non-epithelial MPM in the chemotherapy group was only 8.
8 months [3], indicating that " Y medicine + O 
 

 




 
Medicine, "the two-immune drug therapy compared to chemotherapy in first-line can for all types of malignant pleural mesothelioma patients bring a significant overall survival benefit and long-lasting, in a milestone or malignant pleural mesothelioma therapeutic areas
.

 
" Chinese Society of Clinical Oncology (CSCO) Guidelines for the Clinical Application of Immune Checkpoint Inhibitors (2021 edition), nivolumab combined with ipilimumab for the first-line treatment of non-epithelial and epithelioid pleural mesothelioma became the only class I (Class 1 Evidence) and Level II Recommendation (Class 2A Evidence) [4]
.

 Immune Gemini opens a new pattern in the treatment of malignant pleural mesothelioma.
Malignant Pleural Mesothelioma (MPM) is derived from the pleura Rare tumors of mesothelial cells are mainly divided into epithelioid and non-epithelial tumors according to their histological types.
Malignant pleural mesothelioma is characterized by its insidious onset and highly aggressive nature.
Most patients are already at an advanced stage when they are first diagnosed.
Difficulties and poor prognosis.
MPM treatment options are very limited.
The median overall survival of MPM patients is about 1 year, and the 5-year survival rate is less than 10% [2].
The patients urgently need new treatment options to improve the treatment effect.
Extend the survival time, but the results of various clinical treatments are not satisfactory.
 
 

 




 
The "Y drug + O drug combination treatment plan" was confirmed in a multi-center, open-label, randomized phase III clinical trial (CheckMate 743) study: Compared with standard chemotherapy (platinum combined with pemetrexed), this Combined treatment of previously untreated patients with unresectable MPM, the median overall survival (mOS) was extended by 4 months (18.
1 months vs.
14.
1 months), and the median objective response time (mDOR) was increased by 5.
9 months ( 11.
6 months vs.
6.
7 months), the risk of death was reduced by 27% (HR 0.
73; 95% CI: 0.
61-0.
87); the overall survival (OS) of non-epithelial MPM and epithelial MPM in the experimental group was similar, but the standard The mOS of the non-epithelial MPM in the chemotherapy group was only 8.
8 months [3], indicating that the " Y drug + O drug" dual immunological drug therapy compared with chemotherapy can provide patients with all types of malignant pleural mesothelioma in the first line.
to significant and lasting overall survival benefit in having the milestone of malignant pleural mesothelioma therapeutic areas .
In the "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Clinical Application of Immune Checkpoint Inhibitors (2021 Edition)", nivolumab combined with ipilimumab for the first-line treatment of non-epithelial and epithelioid pleural mesothelioma became the only one to obtain I Level (1 type of evidence) and II level of recommendation (2A type of evidence) treatment plan [4] .


 


 

Immune Gemini opens a new pattern in the treatment of malignant pleural mesothelioma.
Compared with chemotherapy,



" Y drug + O drug" is a dual-immune drug therapy that can bring significant and long-lasting overall survival to patients with all types of malignant pleural mesothelioma in the first line Benefit inThe treatment of malignant pleural mesothelioma is a landmark
.




One step ahead, Jiahui provides Y medicine services for domestic patients.
Jiahui provides Y medicine services for domestic patients.
Jiahui provides Y medicine services for domestic patients.
Y medicine is the first and only approved CTLA in China.
-4 inhibitors, mainly by inhibiting the binding of CTLA-4 of activated T cells to B7 of antigen-presenting cells, break immune tolerance and enhance T cell activity [5] .
As early as 2011, the FDA approved Drug Y for the treatment of advanced melanoma .
PD-1 inhibitor nivolumab (drug O) combined with CTLA-4 inhibitor ipilimumab (drug Y) is considered to have a potential synergistic mechanism: drug Y helps activate and proliferate T cells, while drug O The drug helps existing T cells to find tumors.
Some T cells activated by Y drug can differentiate into memory T cells, which is expected to achieve long-term immune response .
This dual checkpoint inhibitor combination therapy was approved in October 2015 and became the world's first immuno-oncology drug combination therapy approved by regulatory agencies.
It has now been approved for marketing by F DA for 6 tumor types, and its indications cover: melanoma , Advanced renal cell carcinoma, treated MSI-H/dMMR metastatic colorectal cancer, hepatocellular carcinoma, metastatic non-small cell lung cancer, malignant pleural mesothelioma .
Whether it is the malignant pleural mesothelioma that has been approved in China or more indications approved by the FDA, the combination of Y drugs and "Y drugs + O drugs" has shown the potential to bring long-term survival benefits to cancer patients .
As a tumor immunotherapy demonstration center established in a non-public hospital, Jiahui International Cancer Center ( Jiahui International Cancer Center) strives to shorten the time for drug approval and procurement at the beginning of the approval of drug Y , and is the first to meet the domestic requirements.
Batch adaptation 



 



 


 
The patients with the syndrome provide Y-drug -based dual immunotherapy-related services to help patients with malignant pleural mesothelioma get the opportunity to use dual immunotherapy as soon as possible, bringing significant and long-lasting overall survival benefits
.

 
Jiahui International Oncology Center takes "frontier, standard, and safe" as its diagnosis and treatment purpose, has a professional and strong team strength, and has rich experience in immunotherapy and drug safety management
.
As a strategic partner of Massachusetts General Hospital, the Jiahui Medical and Nursing Team is committed to providing patients with immunotherapy pre-medication evaluation, use and post-medication safety monitoring services based on international standards, and is always one step ahead to strive for more for patients Treatment opportunities, and provide personalized diagnosis and treatment plans and high-quality medical services that comply with international standards
.

 
Reference materials:
[ 1] https:// [ 2] Chinese Medical Doctor Association Tumor Multidisciplinary Diagnosis and Treatment Committee.
Chinese Malignant Pleural Mesothelioma Clinical Diagnosis and Treatment Guide (2021 Edition)[J].
Chinese Journal of Oncology,2021,43(04):383-394.

[3]Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D , Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Lancet.
2021 Jan 30;397(10272):375-386.
doi: 10.
1016/S0140-6736(20)32714-8.
Epub 2021 Jan 21.
Erratum in: Lancet.
2021 Feb 20;397(10275):670.
PMID: 33485464 .

[ 4] "immune checkpoint inhibitors clinical application Guide" 2021 version of CSCO Guide
[ 5] He Jie "Introduction to Oncology" 2nd edition, people's health Press
  Y to suppress drug as the first and only approved CTLA-4 It mainly inhibits the combination of CTLA-4 of activated T cells and B7 of antigen-presenting cells to break immune tolerance and enhance T cell activity [5].
As early as 2011, the FDA has approved drug Y for the treatment of advanced melanoma 


.

 
PD-1 inhibitor nivolumab (drug O) combined with CTLA-4 inhibitor ipilimumab (drug Y) is considered to have a potential synergistic mechanism: drug Y helps activate and proliferate T cells, while drug O The drug helps existing T cells to find tumors.
Some T cells activated by Y drug can differentiate into memory T cells, which is expected to achieve long-term immune response
.
This dual checkpoint inhibitor combination therapy was approved in October 2015 and became the world's first immuno-oncology drug combination therapy approved by regulatory agencies.
It has now been approved for marketing by F DA for 6 tumor types, and its indications cover: melanoma , Advanced renal cell carcinoma, treated MSI-H/dMMR metastatic colorectal cancer, hepatocellular carcinoma, metastatic non-small cell lung cancer, malignant pleural mesothelioma
.

 
Whether it is the malignant pleural mesothelioma that has been approved in China or more indications approved by the FDA, the combination of Y drugs and "Y drugs + O drugs" has shown the potential to bring long-term survival benefits to cancer patients
.

 
As a tumor immunotherapy demonstration center established in a non-public hospital, Jiahui International Cancer Center ( Jiahui International Cancer Center) strives to shorten the time for drug approval and procurement at the beginning of the approval of drug Y , and is the first to meet the domestic requirements.
batch adaptation syndrome patient with drug Y is based on double immunotherapy-related services to help patients with malignant pleural mesothelioma access to dual-use immunotherapy as soon as possible, bring significant and lasting benefit in overall survival
.

 
Jiahui International Oncology Center takes "frontier, standard, and safe" as its diagnosis and treatment purpose, has a professional and strong team strength, and has rich experience in immunotherapy and drug safety management
.
As a strategic partner of Massachusetts General Hospital, the Jiahui Medical and Nursing Team is committed to providing patients with immunotherapy pre-medication evaluation, use and post-medication safety monitoring services based on international standards, and is always one step ahead to strive for more for patients Treatment opportunities, and provide personalized diagnosis and treatment plans and high-quality medical services that comply with international standards
.

 
Reference materials:
[ 1] https:// [ 2] Chinese Medical Doctor Association Tumor Multidisciplinary Diagnosis and Treatment Committee.
Chinese Malignant Pleural Mesothelioma Clinical Diagnosis and Treatment Guide (2021 Edition)[J].
Chinese Journal of Oncology,2021,43(04):383-394.

[3]Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D , Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Lancet.
2021 Jan 30;397(10272):375-386.
doi: 10.
1016/S0140-6736(20)32714-8.
Epub 2021 Jan 21.
Erratum in: Lancet.
2021 Feb 20;397(10275):670.
PMID: 33485464 .

[ 4] "immune checkpoint inhibitors clinical application Guide" 2021 version of CSCO Guide
[ 5] He Jie "Introduction to Oncology" 2nd edition, people's Medical Publishing House
 


has been FDAapproved the listing of six tumor types, indications Covers: melanoma, advanced renal cell carcinoma, treated MSI-H/dMMR metastatic colorectal cancer, hepatocellular carcinoma, metastatic non-small cell lung cancer, malignant pleural mesothelioma



Jiahui International Cancer Center ( Jiahui International's Cancer Center) at the beginning of the approval to market the drug Y and strive to shorten the drug approval, procurement and other aspects of time, the first to adapt to meet the domestic approval certificate provided Y patients with drug -based immunotherapy double Related service



reference materials:
[ 1] https:// [ 2] Chinese Medical Doctor Association Multidisciplinary Tumor Diagnosis and Treatment Professional Committee.
Chinese Malignant Pleural Mesothelioma Clinical Diagnosis and Treatment Guidelines (2021 Edition)[J].
Chinese Journal of Oncology,2021,43(04):383-394.

[3]Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D , Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Lancet.
2021 Jan 30;397(10272):375-386.
doi: 10.
1016/S0140-6736(20)32714-8.
Epub 2021 Jan 21.
Erratum in: Lancet.
2021 Feb 20;397(10275):670.
PMID: 33485464 .

[ 4] "immune checkpoint inhibitors clinical application Guide" 2021 version of CSCO Guide
[ 5] "Introduction to Oncology" He Jie 2nd edition, people's Medical Publishing House
  references:
[ 1]https:// https://
[ 2] China Professional Committee of Multidisciplinary Tumor Diagnosis and Treatment of Medical Doctor Association.
Guidelines for the Clinical Diagnosis and Treatment of Malignant Pleural Mesothelioma in China (2021 Edition)[J].
Chinese Journal of Oncology,2021,43(04):383-394.

[3]Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Lancet.
2021 Jan 30;397(10272):375 -386.
doi: 10.
1016/S0140-6736(20)32714-8.
Epub 2021 Jan 21.
Erratum in: Lancet.
2021 Feb 20;397(10275):670.
PMID: 33485464.

[4] "Guidelines for Clinical Application of Immune Checkpoint Inhibitors" 2021 edition of CSCO Guidelines
[ 5] Hejie "Introduction to Oncology" 2nd edition, People's Medical Publishing House


scientifically reduces the use of antibiotics with high drug resistance rates to ensure that patients' lives and health are effectively reduced.
Medical insurance cost